Ultragenyx Pharmaceutical | RARE - Current Assets

Stock Price
24.10
Daily Change
-0.18 -0.74%
Monthly
21.41%
Yearly
-36.73%
Q2 Forecast
24.26

Ultragenyx Pharmaceutical reported $643.21M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Immunic USD 39.27M 20.57M Sep/2025
Insmed USD 1.79B 137.6M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Kyowa Hakko Kirin JPY 493.35B 2.55B Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xoma USD 110.71M 5.78M Sep/2025